Evidence map›Paper›PMID 42291337›Full record

ArticleTranslational lung cancer research2026

The impact of neoadjuvant chemoimmunotherapy on pulmonary function in non-small cell lung cancer patients.

Ao Zeng, Zhilong Xu, Abudumijiti Abuduwayiti, Jiarui Wang, Yanze Yin, Keyi Chen, Mengtao Wang, Xiao Zhou, Jie Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ao Zeng *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhilong Xu *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Abudumijiti AbuduwayitiDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Jiarui WangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Yanze YinDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Keyi ChenDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Mengtao WangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiao ZhouDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Jie DaiDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Perioperative chemoimmunotherapy has suggested a survival benefit in patients with locally-advanced non-small cell lung cancer (NSCLC). This study aims to investigate whether neoadjuvant chemoimmunotherapy influences pulmonary function (PF). Methods: A total of 253 patients with NSCLC who received neoadjuvant chemoimmunotherapy and tumor resection from May 2019 to January 2023 were included. The PF before and after neoadjuvant therapy was compared using a paired t-test, and the difference in the changes of PF between patients with and without chronic obstructive pulmonary disease (COPD) were compared by covariance analysis. Logistic regression analysis was performed to analyze factors influencing the change of PF. Results: The median age was 64 years. The rate of major pathologic response (MPR) was 53.4%, and 11.5% of patients had grade III-IV adverse events. After neoadjuvant chemoimmunotherapy, forced expiratory volume in one second (FEV1) (2.34 Conclusions: An improvement in pulmonary ventilation function was observed in NSCLC patients after neoadjuvant chemoimmunotherapy. This improvement may potentially offer additional opportunities for surgical intervention in NSCLC patients with COPD.

Indexed as

chronic obstructive pulmonary disease (COPD)neoadjuvant chemoimmunotherapyNon-small cell lung cancer (NSCLC)obstructive pneumonia/atelectasispulmonary function (PF)

Identifiers

PMID42291337
PMCPMC13263859

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.